文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症晶体液精准复苏(PRECISE)试验:试验方案

The Precision Resuscitation With Crystalloids in Sepsis (PRECISE) Trial: A Trial Protocol.
PubMed 文献 · JAMA Netw Open · 2024-09-03
一句话结论PRECISE试验将验证:对脓毒症D组亚表型患者,通过电子病历警报提醒使用平衡晶体液替代生理盐水,能否降低30天住院死亡率。

PRECISE试验是一项平行组、多医院、单盲、实用性随机临床试验,将在Emory Healthcare系统的6家医院开展。研究对象为急诊科或ICU中疑似D组感染、且临床医生已开具生理盐水医嘱的患者,随机分为常规治疗组和干预组;干预组通过电子病历警报提醒临床医生使用平衡晶体液而非生理盐水。主要结局为30天住院死亡率,次要结局包括ICU入住、院内死亡、接受血管活性药物、接受新的肾脏替代治疗和接受机械通气(均限于随机化后30天研究期内发生的事件)。研究采用意向性治疗分析,并使用经过验证的机器学习算法,基于常规生命体征(体温、心率、呼吸频率和血压)前瞻性识别和入组D组脓毒症患者。

要点

  • PRECISE试验在6家医院开展,针对急诊科或ICU中疑似D组感染、且临床医生已开具生理盐水医嘱的患者。
  • 干预措施为电子病历警报,提醒临床医生使用平衡晶体液替代生理盐水。
  • 主要结局为30天住院死亡率;次要结局包括ICU入住、院内死亡、血管活性药物、新的肾脏替代治疗和机械通气。
  • 采用意向性治疗分析,使用经过验证的机器学习算法,基于常规生命体征(体温、心率、呼吸频率和血压)前瞻性识别D组脓毒症患者。
  • 此前报告的脓毒症亚表型(D组)显示,与生理盐水相比,平衡晶体液可带来显著的死亡率获益。

适用人群与场景

  • 在Emory Healthcare系统6家医院急诊科或ICU中,疑似D组感染且临床医生已开具生理盐水医嘱的患者。
  • 使用常规生命体征(体温、心率、呼吸频率和血压)通过经过验证的机器学习算法前瞻性识别D组脓毒症患者。

处置流程与药物剂量

  • 干预组:电子病历警报在急诊科和ICU出现,提醒临床医生使用平衡晶体液而非生理盐水。
  • 对照组:常规治疗。

研究设计与关键结果

  • 研究类型:平行组、多医院、单盲、实用性随机临床试验,计划在6家医院开展,采用意向性治疗分析。
  • 主要结局:30天住院死亡率。
  • 次要结局:ICU入住、院内死亡、接受血管活性药物、接受新的肾脏替代治疗和接受机械通气(血管活性药物、肾脏替代治疗和机械通气仅计入随机化后30天研究期内发生的事件)。
  • 此前报告的脓毒症亚表型(D组)显示,与生理盐水相比,平衡晶体液可带来显著的死亡率获益。

证据类型、等级与局限

  • 证据类型:试验方案(随机临床试验方案)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,使用经过验证的机器学习算法,脓毒症精准复苏可能从根本上重新定义国际静脉液体复苏标准。
  • 对于疑似D组感染且临床医生已开具生理盐水医嘱的患者,干预措施为电子病历警报提醒使用平衡晶体液;该措施的有效性尚待试验结果验证。

指南或共识出处

  • ClinicalTrials.gov Identifier: NCT06253585。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Intravenous fluids are an essential part of treatment in sepsis, but there remains clinical equipoise on which type of crystalloid fluids to use in sepsis. A previously reported sepsis subphenotype (ie, group D) has demonstrated a substantial mortality benefit from balanced crystalloids compared with normal saline.

OBJECTIVE: To test the hypothesis that targeting balanced crystalloids to patients with group D sepsis through an electronic health record (EHR) alert will reduce 30-day inpatient mortality.

DESIGN, SETTING, AND PARTICIPANTS: The Precision Resuscitation With Crystalloids in Sepsis (PRECISE) trial is a parallel-group, multihospital, single-blind, pragmatic randomized clinical trial to be conducted at 6 hospitals in the Emory Healthcare system. Patients with suspicion of group D infection in whom a clinician initiates an order for normal saline in the emergency department (ED) or intensive care unit (ICU) will be randomized to usual care and intervention arms.

INTERVENTION: An EHR alert that appears in the ED and ICUs to nudge clinicians to use balanced crystalloids instead of normal saline.

MAIN OUTCOMES AND MEASURES: The primary outcome is 30-day inpatient mortality. Secondary outcomes are ICU admission, in-hospital mortality, receipt of vasoactive drugs, receipt of new kidney replacement therapy, and receipt of mechanical ventilation (vasoactive drugs, kidney replacement therapy, and mechanical ventilation are counted if they occur after randomization and within the 30-day study period). Intention-to-treat analysis will be conducted.

DISCUSSION: The PRECISE trial may be one of the first precision medicine trials of crystalloid fluids in sepsis. Using routine vital signs (temperature, heart rate, respiratory rate, and blood pressure), available even in low-resource settings, a validated machine learning algorithm will prospectively identify and enroll patients with group D sepsis who may have a substantial mortality reduction from used of balanced crystalloids compared with normal saline.

RESULTS: On finalizing participant enrollment and analyzing the data, the study's findings will be shared with the public through publication in a peer-reviewed journal.

CONCLUSIONS: With use of a validated machine learning algorithm, precision resuscitation in sepsis could fundamentally redefine international standards for intravenous fluid resuscitation.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06253585.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Bhavani SV, Holder A, Miltz D, et al. The Precision Resuscitation With Crystalloids in Sepsis (PRECISE) Trial: A Trial Protocol. JAMA Netw Open. 2024. PMID: 39292459. doi:10.1001/jamanetworkopen.2024.34197

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。